Merck Millipore acquires rights for Biotest microbiology products
Merck Millipore now has exclusive rights to sell Biotest microbiology products in Australia and New Zealand.
In 2011, Merck Millipore acquired German company Biotest, an innovative industrial microbiology company with capabilities in ready-to-use media and hygiene monitoring. Its products are targeted at the pharmaceutical and food and beverage segments.
Biotest’s microbiology products, previously marketed by either of their two trading companies, Heipha and Hycon, are now exclusively available through Merck Millipore. Technical support for the products is also offered.
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
Optics11 Life appoints Jacquelien ten Dam as CEO
Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...
Epilepsy pioneer elected President of Aust Academy of Science
Laureate Professor Sam Berkovic — one of the world's most respected neurologists...
